cilostazol has been researched along with Intracranial Hemorrhages in 8 studies
Intracranial Hemorrhages: Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 9.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The Cilostazol Stroke Prevention Study 2 (CSPS 2) showed that cilostazol significantly reduced the risk of stroke by 25." | 7.80 | Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2014) |
| " As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies." | 6.58 | Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 5.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| " Randomized clinical trials that compared cilostazol to aspirin and reported the endpoints of ischemic stroke, intracranial hemorrhage and any bleeding were included." | 5.12 | Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. ( Barrett, KM; Brott, TG; Ertekin-Taner, N; Gopal, N; Lin, MP; Meschia, JF; Ross, OA, 2021) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The Cilostazol Stroke Prevention Study 2 (CSPS 2) showed that cilostazol significantly reduced the risk of stroke by 25." | 3.80 | Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2014) |
| " As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies." | 2.58 | Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018) |
| "Stroke is the second cause of mortality worldwide, and intravenous administration of tissue plasminogen activator (t-PA) within 3 h of symptom onset is the only treatment proven effective for re-establishment of cerebral blood flow following acute ischemic stroke." | 2.47 | Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke. ( Hara, H; Shimazawa, M, 2011) |
| "Cilostazol is an antiplatelet agent that can induce the regression of atherosclerosis." | 1.40 | Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy. ( Narumi, S; Ohba, H; Oura, K; Sasaki, M; Terayama, Y; Uwano, I; Yamaguchi Oura, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SM | 1 |
| Jung, JM | 1 |
| Kim, BJ | 1 |
| Lee, JS | 1 |
| Kwon, SU | 1 |
| Lin, MP | 1 |
| Meschia, JF | 1 |
| Gopal, N | 1 |
| Barrett, KM | 1 |
| Ross, OA | 1 |
| Ertekin-Taner, N | 1 |
| Brott, TG | 1 |
| Imai, T | 1 |
| Matsukawa, H | 1 |
| Takagi, T | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 2 |
| Hara, H | 2 |
| Zhang, JJ | 1 |
| Liu, X | 1 |
| Uchiyama, S | 1 |
| Shinohara, Y | 1 |
| Katayama, Y | 1 |
| Yamaguchi, T | 1 |
| Handa, S | 1 |
| Matsuoka, K | 1 |
| Ohashi, Y | 1 |
| Tanahashi, N | 1 |
| Yamamoto, H | 1 |
| Genka, C | 1 |
| Kitagawa, Y | 1 |
| Kusuoka, H | 1 |
| Nishimaru, K | 1 |
| Tsushima, M | 1 |
| Koretsune, Y | 1 |
| Sawada, T | 1 |
| Hamada, C | 1 |
| Yamaguchi Oura, M | 1 |
| Sasaki, M | 1 |
| Ohba, H | 1 |
| Narumi, S | 1 |
| Oura, K | 1 |
| Uwano, I | 1 |
| Terayama, Y | 1 |
| Guo, JJ | 1 |
| Xu, E | 1 |
| Lin, QY | 1 |
| Zeng, GL | 1 |
| Xie, HF | 1 |
4 reviews available for cilostazol and Intracranial Hemorrhages
| Article | Year |
|---|---|
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Cilostazol; Female; Humans; Intracranial Hemorrhages; Ische | 2021 |
Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hema | 2018 |
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Endothelium, Vascular; Humans; Intracrania | 2011 |
1 trial available for cilostazol and Intracranial Hemorrhages
| Article | Year |
|---|---|
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr | 2009 |
3 other studies available for cilostazol and Intracranial Hemorrhages
| Article | Year |
|---|---|
The phosphodiesterase III inhibitor cilostazol protects the brain microvasculature from collagenase injury.
Topics: Administration, Oral; Animals; Brain; Cardiovascular Agents; Cells, Cultured; Cilostazol; Collagen T | 2017 |
Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2.
Topics: Cilostazol; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Risk Factors; Stroke; | 2014 |
Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy.
Topics: Aged; Carotid Artery Diseases; Cilostazol; Female; Fibrosis; Humans; Imaging, Three-Dimensional; Int | 2014 |